Catalent Owners | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Catalent Inc.

Catalent Inc. | Ownership

Companies that own Catalent Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

T. Rowe Price Associates, Inc.

16,366,611

11.3%

309,312

0.09%

06/30/2018

The Vanguard Group, Inc.

11,740,434

8.1%

80,155

0.02%

06/30/2018

BlackRock Fund Advisors

10,786,659

7.45%

-2,822,212

0.02%

06/30/2018

Henderson Global Investors Ltd.

6,400,737

4.42%

266,183

0.12%

06/30/2018

JPMorgan Investment Management, Inc.

5,152,755

3.56%

1,235,831

0.07%

06/30/2018

Champlain Investment Partners LLC

3,757,900

2.59%

130,510

1.42%

06/30/2018

SSgA Funds Management, Inc.

3,707,349

2.56%

-1,030,881

0.01%

06/30/2018

William Blair Investment Management LLC

3,459,196

2.39%

14,149

0.27%

06/30/2018

Franklin Advisers, Inc.

3,405,819

2.35%

5,819

0.09%

06/30/2018

American Century Investment Management, Inc.

3,052,515

2.11%

183,880

0.11%

06/30/2018

About Catalent

View Profile

Address	14 Schoolhouse Road Somerset New Jersey 08873 United States
Employees	-
Website	http://www.catalent.com
Updated	07/08/2019
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment focuses on the formulation, development, and manufacture of prescription and consumer health soft capsules, softgels, vegicaps and optishell capsules.